Reaction Details Report a problem with these data
Target
Kallikrein-14
Ligand
BDBM50289001
Substrate
n/a
Meas. Tech.
KLK14 Assay
pH
8±n/a
Temperature
310.15±n/a K
Ki
2100±n/a nM
Comments
extracted
Citation
 Wagberg, F; Leonardsson, G Benzoxazinone derivatives for treatment of skin diseases US Patent  US9695194 Publication Date 7/4/2017 
Target
Name:
Kallikrein-14
Synonyms:
KLK-L6 | KLK14 | KLK14_HUMAN | KLKL6 | Kallikrein 14 | Kallikrein-14 | Kallikrein-like protein 6 | hK14
Type:
PROTEIN
Mol. Mass.:
29136.99
Organism:
Homo sapiens (Human)
Description:
ChEMBL_1282452
Residue:
267
Sequence:
MSLRVLGSGTWPSAPKMFLLLTALQVLAIAMTQSQEDENKIIGGHTCTRSSQPWQAALLAGPRRRFLCGGALLSGQWVITAAHCGRPILQVALGKHNLRRWEATQQVLRVVRQVTHPNYNSRTHDNDLMLLQLQQPARIGRAVRPIEVTQACASPGTSCRVSGWGTISSPIARYPASLQCVNINISPDEVCQKAYPRTITPGMVCAGVPQGGKDSCQGDSGGPLVCRGQLQGLVSWGMERCALPGYPGVYTNLCKYRSWIEETMRDK
  
Inhibitor
Name:
BDBM50289001
Synonyms:
2-(2-Iodo-phenyl)-6,7-dimethoxy-benzo[d][1,3]oxazin-4-one | CHEMBL349763 | US9695194, 18
Type:
Small organic molecule
Emp. Form.:
C16H12INO4
Mol. Mass.:
409.1753
SMILES:
COc1cc2nc(oc(=O)c2cc1OC)-c1ccccc1I
Structure:
Search PDB for entries with ligand similarity: